On Friday, Akebia Therapeutics Inc (NASDAQ: AKBA) opened lower -2.67% from the last session, before settling in for the closing price of $2.62. Price fluctuations for AKBA have ranged from $0.80 to $2.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -10.63% over the past five years. Company’s average yearly earnings per share was noted 70.30% at the time writing. With a float of $251.86 million, this company’s outstanding shares have now reached $261.64 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is 60.08%, operating margin of -31.47%, and the pretax margin is -43.33%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 26.50%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,928. In this transaction CEO and President of this company sold 46,409 shares at a rate of $1.83, taking the stock ownership to the 2,557,921 shares. Before that another transaction happened on Mar 03 ’25, when Company’s SVP, Chief Medical Officer sold 7,144 for $1.83, making the entire transaction worth $13,074. This insider now owns 809,090 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 70.30% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc (AKBA). In the past quarter, the stock posted a quick ratio of 2.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach 0.00 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 5.45 million, a positive change from its year-to-date volume of 3.72 million. As of the previous 9 days, the stock’s Stochastic %D was 64.79%. Additionally, its Average True Range was 0.16.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 74.64%, which indicates a significant increase from 58.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.95% in the past 14 days, which was lower than the 94.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.07, while its 200-day Moving Average is $1.79. Nevertheless, the first resistance level for the watch stands at $2.70 in the near term. At $2.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.93. If the price goes on to break the first support level at $2.47, it is likely to go to the next support level at $2.39. The third support level lies at $2.24 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are currently 261,785K shares outstanding in the company with a market cap of 667.56 million. Presently, the company’s annual sales total 160,180 K according to its annual income of -69,410 K. Last quarter, the company’s sales amounted to 46,500 K and its income totaled -22,800 K.
